ADAM8 and breast carcinoma: In agreement, CRISPR/Cas9 knockout of ADAM8 in human breast carcinoma cells resulted in the same results (Cook et al., 2022), which indicates that the phenomenon of ADAM8 is not limited to a specific cancer type.